Reuters logo
BRIEF-Dimension Therapeutics begins early-stage study testing gene therapy DTX301
August 31, 2017 / 12:16 PM / 3 months ago

BRIEF-Dimension Therapeutics begins early-stage study testing gene therapy DTX301

Aug 31 (Reuters) - Dimension Therapeutics Inc

* Dimension therapeutics commences patient dosing in global, multi-center phase 1/2 clinical trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency

* Dimension Therapeutics Inc - ‍initial data from company’s phase 1/2 study anticipated by late 2017​

* Dimension Therapeutics Inc - ‍twelve trial sites recruiting patients with OTC deficiency in United States, United Kingdom, Spain, and Canada​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below